Payment overview · 2025
General Payments
$2,931.74
125 reported records · 26 companies
Healthcare provider profile · identity verified
Alan J Bowers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARRERO, LA · NPI 1306832886
Verified facts
What the public records show
CMS Open Payments records show Alan J Bowers, MD received $2,931.74 in general payments during 2025 across 125 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 556 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 556 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $433.96 | 14.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $347.34 | 11.8% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $339.82 | 11.6% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $255.55 | 8.7% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $212.06 | 7.2% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $172.64 | 5.9% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $165.78 | 5.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.96 | 5.6% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $115.60 | 3.9% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $113.03 | 3.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.30 | 3.5% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $76.70 | 2.6% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $71.36 | 2.4% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $65.26 | 2.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.30 | 1.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.48 | 1.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.97 | 1.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.93 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.99 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.50 | 0.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $21.04 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.60 | 0.7% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $19.45 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.20 | 0.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $18.46 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.46 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,886.74 | 124 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $357.38 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $336.37 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $277.81 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $192.99 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $178.31 | 11 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $154.23 | 6 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.34 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $113.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $108.44 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $108.44 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $108.44 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.30 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $100.46 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $78.94 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $78.94 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $76.70 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $71.36 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.20 | 4 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $65.26 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.87 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $55.87 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.69 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.19 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $10.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 556 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 361 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 245 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 146 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 168 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 246 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
146 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
107 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
361 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 41 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
556 | 56 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
139 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
168 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
186 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
246 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
556 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 897 | 190 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 803 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 798 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 695 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 638 | 161 |
| Gabapentin | Gabapentin | 599 | 122 |
| Eliquis | Apixaban | 556 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 544 | 138 |
| Fluticasone Propionate | Fluticasone Propionate | 448 | 148 |
| Losartan Potassium | Losartan Potassium | 391 | 91 |
| Furosemide | Furosemide | 384 | 84 |
| Lisinopril | Lisinopril | 382 | 95 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 373 | 120 |
| Clonazepam | Clonazepam | 368 | 71 |
| Farxiga | Dapagliflozin Propanediol | 361 | 47 |
| Omeprazole | Omeprazole | 359 | 84 |
| Potassium Chloride | Potassium Chloride | 324 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 314 | 73 |
| Metformin Hcl | Metformin Hcl | 292 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 66 |
| Mirtazapine | Mirtazapine | 257 | 63 |
| Alprazolam | Alprazolam | 256 | 58 |
| Ozempic | Semaglutide | 246 | 46 |
| Jardiance | Empagliflozin | 245 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 238 | 75 |
| Trazodone Hcl | Trazodone Hcl | 235 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 233 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 228 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 228 | 51 |
| Carvedilol | Carvedilol | 220 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 210 | 43 |
| Simvastatin | Simvastatin | 210 | 48 |
| Donepezil Hcl | Donepezil Hcl | 189 | 36 |
| Trulicity | Dulaglutide | 186 | 37 |
| Meloxicam | Meloxicam | 184 | 46 |
| Tramadol Hcl | Tramadol Hcl | 178 | 38 |
| Januvia | Sitagliptin Phosphate | 176 | 32 |
| Lorazepam | Lorazepam | 175 | 32 |
| Sertraline Hcl | Sertraline Hcl | 170 | 39 |
| Mounjaro | Tirzepatide | 168 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 166 | 33 |
| Allopurinol | Allopurinol | 164 | 38 |
| Montelukast Sodium | Montelukast Sodium | 163 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 160 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 35 |
| Megestrol Acetate | Megestrol Acetate | 149 | 40 |
| Pregabalin | Pregabalin | 147 | 33 |
| Linzess | Linaclotide | 146 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 37 |
| Valsartan | Valsartan | 134 | 33 |
| Ezetimibe | Ezetimibe | 133 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 22 |
| Glimepiride | Glimepiride | 132 | 38 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 131 | 31 |
| Clonidine Hcl | Clonidine Hcl | 126 | 36 |
| Baclofen | Baclofen | 125 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 125 | 36 |
| Metformin Hcl Er | Metformin Hcl | 122 | 34 |
| Xarelto | Rivaroxaban | 120 | 14 |
| Bupropion Xl | Bupropion Hcl | 116 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 38 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 24 |
| Lactulose | Lactulose | 107 | 19 |
| Synthroid | Levothyroxine Sodium | 107 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 20 |
| Benazepril Hcl | Benazepril Hcl | 104 | 25 |
| Memantine Hcl | Memantine Hcl | 101 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 100 | 81 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 15 |
| Bumetanide | Bumetanide | 96 | 26 |
| Famotidine | Famotidine | 96 | 23 |
| Mupirocin | Mupirocin | 96 | 48 |
| Levetiracetam | Levetiracetam | 92 | 19 |
| Ibuprofen | Ibuprofen | 88 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 20 |
| Spironolactone | Spironolactone | 86 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 83 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 81 | 23 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 81 | 17 |
| Atenolol | Atenolol | 79 | 20 |
| Prednisone | Prednisone | 79 | 17 |
| Buspirone Hcl | Buspirone Hcl | 78 | 15 |
| Diazepam | Diazepam | 78 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 24 |
| Finasteride | Finasteride | 76 | 19 |
| Latanoprost | Latanoprost | 73 | 13 |
| Glipizide Er | Glipizide | 72 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 17 |
| Nystatin | Nystatin | 68 | 31 |
| Ramipril | Ramipril | 67 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 65 | 23 |
| Alendronate Sodium | Alendronate Sodium | 64 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 47 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 62 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Nifedipine Er | Nifedipine | 61 | 12 |
| Entresto | Sacubitril/Valsartan | 60 | 11 |
| Ondansetron Odt | Ondansetron | 60 | 17 |
| Insulin Aspart Flexpen | Insulin Aspart | 58 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | suppressed |
| Fluconazole | Fluconazole | 53 | 27 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Vascepa | Icosapent Ethyl | 53 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 11 |
| Estradiol | Estradiol | 52 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 12 |
| Olanzapine | Olanzapine | 50 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 49 | 14 |
| Cephalexin | Cephalexin | 49 | 37 |
| Divalproex Sodium | Divalproex Sodium | 49 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 12 |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Risperidone | Risperidone | 49 | suppressed |
| Temazepam | Temazepam | 49 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 11 |
| Lovastatin | Lovastatin | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Naproxen | Naproxen | 42 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Lubiprostone | Lubiprostone | 41 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | 36 |
| Bethanechol Chloride | Bethanechol Chloride | 40 | suppressed |
| Lacosamide | Lacosamide | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 28 |
| Ketoconazole | Ketoconazole | 39 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 11 |
| Levofloxacin | Levofloxacin | 36 | 24 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 33 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 34 | 19 |
| Brilinta | Ticagrelor | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Etodolac | Etodolac | 33 | 13 |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Belsomra | Suvorexant | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 19 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Verapamil Sr | Verapamil Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 12 |
| Restasis | Cyclosporine | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Bicalutamide | Bicalutamide | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 16 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 14 | suppressed |
| Efavirenz | Efavirenz | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,931.74 · 125 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, LOREEV XR, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, Natroba, Ozempic, PIFELTRO, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, Spinosad, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VYNDAQEL, Veozah, Wegovy, Yeztugo, ZAVZPRET, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error